Korea Institute of Toxicology signs PATH/TOX SYSTEM License Agreement

Xybion welcomes a new client to its worldwide PATH/TOX SYSTEM community. PATH/TOX SYSTEM, in production in 9 countries throughout North America, Europe and Asia, is a preclinical safety assesment data acquisition, management and reporting system.

Cedar Knolls, NJ (Sept 27, 2002) – Xybion Medical Systems Corporation (Xybion), a developer and supplier of comprehensive Preclinical Data Management Systems, including its industry-leading PATH/TOX SYSTEM, announced today that the Korea Institute of Toxicology (KIT) has licensed PATH/TOX SYSTEM Open VMS Version 4.2.2 for collection, management and reporting of data related to its chemical and pharmaceutical safety assessment research being conducted at its Daejeon, Korea facility.

KIT is Koreas largest independent toxicology research organization providing services to the chemical and pharmaceutical industries within Korea and throughout Asia. Prior to 2002, KIT was an integral part of the Korea Research Institute of Chemical Technology.

KITs decision to replace its current software solution by licensing PATH/TOX SYSTEM further demonstrates the preclinical marketplaces confidence in the high quality solutions provided by Xybion and in its world class customer service", said Jennifer Feldmann, Vice-President of Xybion. We are pleased that KIT has selected Xybion for its preclinical data management solution partner. PATH/TOX SYSTEM and Xybions support services will play a critical role in KITs expansion into the Asian toxicology research marketplace."

Xybions PATH/TOX SYSTEM is a suite of tightly integrated modules that addresses all aspects of preclinical data acquisition, management and reporting. It is in production in 9 different countries throughout North America, Europe and Asia. Clients have the flexibility to license those modules and options needed to support their study protocols and processes providing a client-centric custom solution. Xybions products are industry leaders and are used by some of the worlds largest and most prestigious pharmaceutical and chemical companies to assess compound safety while reducing the time to market for a new drug or chemical.